Gesamtlänge aller Episoden: 5 days 18 hours 23 minutes
Sara A. Hurvitz, MD, FACP - Drug-Induced Interstitial Lung Disease and Breast Cancer: Knowing the Odds and Managing the Risk
Aditya Bardia, MD, MPH - Keeping to Target in mTNBC: Optimising Outcomes With Antibody-Drug Conjugates in Practice
Arndt Vogel, MD - Options and Opportunities in Cholangiocarcinoma: Novel Approaches for Targeting FGFR Alterations
Geoffrey Ku, MD - Here’s The Challenge! Overcoming Tumour Heterogeneity in Gastric/GEJ Cancers
Nick Pavlakis, MBBS, PLD / Kohei Shitara, MD - The Evolution of Treatment for Advanced Gastric and Oesophageal Cancers: New Insights From Key Congresses
Julia Rotow, MD / Javier Cortés, MD - HER3-Targeted Therapies: How Might These Benefit Our Patients?
Emmanuella Guenova, MD, PhD - ‘T’ing Up Management of Mycosis Fungoides and Sézary Syndrome: Evaluating Blood Involvement and Its Impact on Patient Care
Stefano Fanti, MD - Evolving Evidence of Radioligand Therapy in Metastatic Prostate Cancer: A 2023 Clinical Round-Up From Key Congresses
Kevin Harrington, PhD, FRCR, FRCP - When CPS is Between 1 and 19, How Would You Manage Recurrent/Metastatic SCCHN?
Jun-ichi Nishimura, MD, PhD / Austin Kulasekararaj, MD, FRCPath / Jeffrey Szer, MBBS, FRACP - Haemolysis in Paroxysmal Nocturnal Haemoglobinuria: Applying Assessment and Mitigation Strategies for Patients Receiving Complement Inhibitors